| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
CMP3a targets NEK2 (NIMA-related kinase 2), a serine/threonine kinase that plays a critical role in cell cycle progression and centrosome duplication. It acts as an inhibitor, blocking the kinase activity of NEK2. By inhibiting NEK2, it disrupts the function of EZH2, a histone methyltransferase involved in gene regulation.
|
|---|---|
| ln Vitro |
With IC50 values of 0.064, 0.031, and 0.161 µM for AsPC-1, PL45, and MIA PaCa-2 cells, respectively, Nek2-IN-4 (72 h) suppresses cell proliferation [1].
In vitro, CMP3a is a potent NEK2 kinase inhibitor with anticancer activity. It inhibits the growth of glioma stem cells. Its activity as a NEK2 inhibitor makes it a valuable tool for studying the role of NEK2 in cancer. |
| ln Vivo |
In vivo, CMP3a efficiently attenuated GBM growth in a mouse model. It exhibited a synergistic effect with radiotherapy. This demonstrates its potential as a therapeutic agent for glioblastoma.
|
| Enzyme Assay |
CMP3a is evaluated in cell-free kinase assays using purified NEK2 enzyme. The compound is incubated with NEK2, ATP, and a substrate, and the inhibition of kinase activity is measured. IC50 values are determined to quantify the potency of NEK2 inhibition.
|
| Cell Assay |
Cell Proliferation Experiment[1]
Cell Types: AsPC-1, PL45, MIA PaCa-2 Cell Tested Concentrations: Incubation Duration: 72 hrs (hours) Experimental Results: demonstrated anti-proliferative activity against AsPC-1, PL45, MIA PaCa-2 cells, IC50 were respectively 0.064, 0.031, 0.161 µM. CMP3a is assessed in cell-based assays using glioma stem cells and other cancer cell lines. Cells are treated with CMP3a, and cell proliferation, apoptosis, and NEK2 activity are measured. The compound's ability to inhibit NEK2 and disrupt EZH2 function is evaluated. |
| Animal Protocol |
CMP3a is administered in animal models to evaluate its antitumor efficacy. In a mouse model of glioblastoma, it attenuated GBM growth and exhibited a synergistic effect with radiotherapy. Efficacy is assessed by measuring tumor growth inhibition and survival.
|
| ADME/Pharmacokinetics |
CMP3a has a molecular weight of 568.61 and a molecular formula of C28H27F3N6O2S. It has a CAS number of 2225902-88-3. The compound is soluble in DMSO. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for CMP3a. The compound is for research use only and is not intended for human therapeutic use. It is a NEK2 kinase inhibitor used to study glioblastoma and other cancers.
|
| References | |
| Additional Infomation |
CMP3a is also known as NBI-961. It is a NEK2 kinase inhibitor. It efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. The compound is not approved for clinical use.
|
| Molecular Formula |
C28H27F3N6O2S
|
|---|---|
| Molecular Weight |
568.613194704056
|
| Exact Mass |
568.186
|
| Elemental Analysis |
C, 59.14; H, 4.79; F, 10.02; N, 14.78; O, 5.63; S, 5.64
|
| CAS # |
2225902-88-3
|
| PubChem CID |
134470304
|
| Appearance |
Yellow solid powder
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
40
|
| Complexity |
868
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)C3=CN=C4N3C=CC(=C4)C5=CN(N=C5)CCN(C)C)C(=O)N
|
| InChi Key |
BQODGOMHYSMCGK-QGZVFWFLSA-N
|
| InChi Code |
InChI=1S/C28H27F3N6O2S/c1-17(20-6-4-5-7-21(20)28(29,30)31)39-23-13-24(40-26(23)27(32)38)22-15-33-25-12-18(8-9-37(22)25)19-14-34-36(16-19)11-10-35(2)3/h4-9,12-17H,10-11H2,1-3H3,(H2,32,38)/t17-/m1/s1
|
| Chemical Name |
5-[7-[1-[2-(dimethylamino)ethyl]pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide
|
| Synonyms |
CMP 3a CMP-3a CMP3a
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7587 mL | 8.7934 mL | 17.5867 mL | |
| 5 mM | 0.3517 mL | 1.7587 mL | 3.5173 mL | |
| 10 mM | 0.1759 mL | 0.8793 mL | 1.7587 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
